GLP-1 drugs like Ozempic and Wegovy have rapidly moved from niche diabetes treatments to blockbuster weight loss injections, ...

GLP-1 receptor agonists are associated with a lower risk of dementia than DPP-4 inhibitors in dialysis patients with diabetes.

Popular weight-loss drugs “probably have little or no effect” on a person’s risk of developing one of the 13 obesity-related ...

Tantalizing results from small trials and anecdotes raised hopes that drugs like Ozempic could help. Despite setbacks, ...

The WHO issues its first official guidance on GLP-1 drugs for obesity treatment, as the disease affects over one billion ...

Regular exercise and sufficient protein intake can help maintain muscle and preserve long-term health in patients taking ...

(HealthDay News) — For patients with type 2 diabetes, there is an association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and chronic cough, according to a study published online ...

A new study finds a possible association between GLP-1 drugs like semaglutide and chronic cough, though the authors are ...

Amid soaring global demand for glucagon-like peptide-1 (GLP-1) medications and widespread concerns about affordability and access, the World Health Organization (WHO) released its global comprehensive ...

With the skyrocketing popularity of GLP-1 RAs, some lesser-known side effects, including anemia, are coming to light.

Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally ...